Europe HbA1c Testing Market

Europe HbA1c Testing Market Size

The europe HbA1c testing market was valued at USD 396.5 million in 2024, is expected to have a 11.32 % CAGR from 2025 to 2033, and be worth USD 1040.88 million by 2033 from USD 441.38 million in 2025.

Glycated hemoglobin A1c (HbA1c) testing is a critical diagnostic and monitoring tool that reflects average blood glucose levels over the preceding two to three months by measuring the %age of hemoglobin bound to glucose. In Europe, HbA1c is the gold standard for long-term diabetes management and is increasingly used for diagnosis in accordance with guidelines from the International Diabetes Federation and the World Health Organization. The clinical utility of HbA1c lies in its independence from short-term glucose fluctuations, fasting requirements, or acute stressors, making it ideal for routine screening and therapeutic assessment. As per the European Society of Cardiology, cardiovascular disease patients in primary care settings now undergo annual HbA1c testing as part of metabolic risk evaluation. Furthermore, national health programs in countries like Sweden and the Netherlands have integrated HbA1c into population-based diabetes prevention initiatives, with general practitioners conducting over 25 million HbA1c tests annually across the EU.

MARKET DRIVERS

Escalating Diabetes Prevalence and Early Screening Mandates

The rising burden of diabetes with aging populations, sedentary lifestyles, and obesity is a major factor boosting the growth of the European HbA1c testing market. According to the International Diabetes Federation, 61 million adults in Europe had diabetes in 2023, a figure projected to reach 68 million by 2030. According to the European Centre for Disease Prevention and Control estimates that nearly 18 % of adults with type 2 diabetes remain unaware of their condition, increasing risks of complications. The UK’s National Institute for Health and Care Excellence recommends HbA1c testing for all adults with risk factors, such as BMI over 30 or family history are leading to over 4.2 million diagnostic HbA1c tests performed in primary care in 2023 alone. Similarly, Germany’s statutory health insurance mandates annual HbA1c monitoring for all insured diabetics, generating consistent testing volume.

Integration of HbA1c into Cardiovascular and Metabolic Risk Assessment

The HbA1c testing has expanded beyond diabetes management into broader cardiometabolic risk stratification is significantly enhancing the growth of the European HbA1c testing market. The European Society of Cardiology now includes HbA1c in its guidelines for assessing cardiovascular risk in asymptomatic adults, particularly those with hypertension or dyslipidemia. This integration has led to routine HbA1c inclusion in preventive health checkups across occupational health programs and primary care settings. Additionally, the European Association for the Study of Obesity advocates HbA1c as a key metric in weight management programs, with its correlation with visceral adiposity and insulin resistance.

MARKET RESTRAINTS

Interference from Hemoglobin Variants and Clinical Conditions

The presence of hemoglobinopathies and certain clinical conditions that alter red blood cell turnover, leading to misleading results, is solely hampering the growth of the European HbA1c testing market. Hemoglobin variants such as HbS, HbC, and HbE, though more common in populations of African, Mediterranean, and South Asian descent, are increasingly prevalent in Europe due to migration. The population in countries like Italy, Greece, and the UK carries clinically relevant hemoglobin variants that can cause falsely elevated or suppressed HbA1c readings depending on the assay method. Additionally, conditions like anemia, chronic kidney disease, and recent blood transfusions distort HbA1c interpretation.

Reimbursement Limitations and Fragmented Diagnostic Pathways

Reimbursement policies and fragmented care coordination across European healthcare systems are other attributes limiting the growth of the European HbA1c testing market. While countries like Germany and Sweden provide full coverage for quarterly HbA1c monitoring in diagnosed diabetics, others impose strict limits. According to the European Observatory on Health Systems and Policies, France restricts publicly reimbursed HbA1c tests to twice per year for stable patients, and Spain requires endocrinologist authorization for tests beyond the annual minimum. These restrictions discourage frequent monitoring in primary care, where most diabetes management occurs.

MARKET OPPORTUNITIES

Expansion of Point of Care Testing in Primary and Community Settings

The proliferation of certified point-of-care HbA1c analyzers to enhance diabetes management through immediate results and real-time clinical decision making was creating new opportunities for the growth of the European HbA1c testing market. Unlike central laboratory testing, which can take days, point-of-care devices deliver HbA1c values in under five minutes by enabling same-visit treatment adjustments and patient education. The UK’s Quality and Outcomes Framework incentivizes practices to maintain HbA1c records for over 90 % of their diabetic patients, thereby driving investment in on-site analyzers. Additionally, community pharmacies in the Netherlands and Ireland have launched HbA1c screening services under national pilot programs, reaching underserved populations. The European Commission’s Digital Europe Programme has further supported integration of point-of-care data into electronic health records, ensuring continuity of care.

Adoption of HbA1c in Digital Health and Remote Monitoring Platforms

The integration of HbA1c data into digital therapeutics and remote patient monitoring ecosystems is unlocking new opportunities for chronic disease management, which is expected to bolster the growth of the European HbA1c testing market. Digital health platforms now combine HbA1c results with continuous glucose monitoring, activity tracking, and dietary logs to generate personalized insights and behavioral nudges. Over 1.2 million diabetic patients in the EU were enrolled in digital coaching programs in 2024 that use HbA1c as a key outcome metric. Furthermore, the European Medicines Agency recognizes HbA1c reduction as a valid endpoint in clinical trials for digital therapeutics, accelerating regulatory validation. Companies like mySugr and Omada Health have partnered with payers in France and Sweden to offer bundled services that include quarterly HbA1c testing kits mailed to patients.

MARKET CHALLENGES

Standardization Gaps Across Testing Methodologies and Laboratories

The persistent variability in HbA1c measurement methodologies undermines result comparability and clinical confidence, which is one of the challenges for the growth of the European HbA1c testing market. While the International Federation of Clinical Chemistry and Laboratory Medicine established a reference measurement procedure, implementation varies by country and platform. According to the European External Quality Assessment Service, inter inter-laboratory coefficient of variation for HbA1c in routine practice exceeds the clinically acceptable threshold of 2%. Immunoassay-based systems may overestimate HbA1c in the presence of carbamylated hemoglobin, while enzymatic methods can be affected by high triglyceride levels. These discrepancies are particularly problematic in cross-border care or when patients switch providers. The European Directorate for the Quality of Medicines reports that 18 % of HbA1c proficiency testing failures in 2023 were due to method-specific interferences.

Workforce Shortages and Laboratory Capacity Constraints

The operational challenges from chronic shortages of clinical laboratory professionals and constrained diagnostic capacity are alsexpected o expected to slow the growth of the European HbA1c testing market. The EU faces a deficit of over 35,000 medical laboratory scientists, with vacancy rates exceeding 20% in countries like Romania, Bulgaria, and Portugal. This staffing gap delays sample processing and result reporting, reducing the timeliness of HbA1c monitoring. The average turnaround time for HbA1c in public laboratories in Southern Europe exceeds 72 hours, when compared to 24 hours in Nordic countries.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Technology Insights

The ion exchange segment accounted in holding 42.3% of the European HbA1c Testing Market share in 2024 with its high precision, reproducibility, and alignment with international standardization protocols. This technology separates glycated and non-glycated hemoglobin variants based on charge differences, delivering results that closely correlate with the International Federation of Clinical Chemistry and Laboratory Medicine reference method. HPLC-based systems exhibit the lowest inter-laboratory variability among all HbA1c methodologies, with a coefficient of variation consistently below 2.5% in proficiency testing. National reference laboratories in Germany, France, and the Netherlands predominantly use HPLC platforms from manufacturers like Bio Rad and Tosoh for confirmatory testing and calibration. The European Directorate for the Quality of Medicines recognizes HPLC as the gold standard for method validation in clinical trials involving glycemic endpoints.

The enzymatic assay segment is lucratively growing with an expected CAGR of 9.3% throughout the forecast period, with its compatibility with high-throughput clinical chemistry analyzers already installed in most hospitals and reference laboratories, eliminating the need for dedicated instrumentation. According to the European Federation of Clinical Chemistry and Laboratory Medicine, enzymatic HbA1c assays demonstrated concordance with IFCC reference values in a 2023 multicenter evaluation across 14 EU countries. Major diagnostic companies like Roche and Abbott have integrated enzymatic HbA1c into their core chemistry panels, enabling automatic reflex testing when glucose levels are elevated.

By Type Insights

The benchtop HbA1c analyzer segment was the largest by accounting for a significant share of the European HbA1c Testing Market in 2024. These systems offer high throughput, superior precision, and full compliance with NGSP and IFCC standardization requirements by making them indispensable for centralized testing environments. According to the European Federation of Laboratory Medicine, over 18,000 bench-top HbA1c analyzers are operational across EU clinical laboratories, with platforms from Bio Rad, Siemens Healthineers, and Tosoh dominating the landscape. National health systems reinforce this dominance through procurement policies; the UK’s National Health Service mandates that all HbA1c results used for diabetes diagnosis must originate from accredited bench-top systems participating in external quality assurance schemes. Additionally, benchtop devices support multiplex testing, allowing simultaneous analysis of HbA1c alongside lipid profiles and renal markers in metabolic panels.

The handheld HbA1c devices segment is expected to register the fastest CAGR of 12.1% throughout the forecast period with the expansion of point-of-care testing in primary care, community pharmacies, and diabetes education centers, where immediate results enable real-time clinical decisions. Modern handheld analyzers, such as those from Afinion, Siemens, and Bio Rad, now meet NGSP certification standards by ensuring reliability comparable to laboratory systems. According to the European Primary Care Diabetes Society, over 7,500 general practices in Western Europe adopted certified point-of-care HbA1c devices between 2022 and 2024, with adoption rates exceeding 60% in the Netherlands and Denmark. National incentive programs further accelerate uptake; Germany’s Disease Management Program for Diabetes reimburses quarterly point-of-care HbA1c tests conducted in physician offices. Additionally, pilot programs in Ireland and Spain now allow community pharmacists to perform HbA1c screening for at-risk populations, reaching individuals who avoid traditional healthcare settings.

By End User Insights

The diagnostic laboratories segment held a dominant share of the European HbA1c Testing Market in 2024. These facilities process HbA1c samples from general practitioners, occupational health programs, and hospital outpatient departments by ensuring compliance with national quality frameworks. National external quality assessment schemes, such as DEKS in Germany and UK NEQAS, mandate regular participation, which reinforces methodological consistency and result reliability. The European Commission’s In Vitro Diagnostic Regulation further strengthens laboratory dominance by requiring stringent performance validation for all HbA1c assays used in clinical decision making. Additionally, reference laboratories in countries like France and Sweden provide calibration services for point-of-care devices, anchoring the entire testing ecosystem to centralized standards. This institutional role, combined with economies of scale and regulatory oversight that ensures diagnostic laboratories remain the primary engine of HbA1c testing volume and quality assurance across Europe.

The home care segment is likely to grow with the fastest CAGR of 14.6% throughout the forecast period, owing to the rise of self-monitoring among motivated diabetic patients, digital health integration, and payer-supported remote management programs. According to the European Connected Health Alliance, over 320,000 diabetic patients in the EU used home HbA1c collection kits in 2024, a 68 % increase from 2022. National health systems are beginning to reimburse these services; Sweden’s Vårdgaranti program now covers biannual home HbA1c tests for type 2 diabetics enrolled in digital coaching platforms. Furthermore, the European Medicines Agency accepts home-collected HbA1c data in real-world evidence studies for diabetes therapeutics, validating their clinical utility.

COUNTRY LEVEL ANALYSIS

Germany HbA1c Testing Market Analysis

Germany was the top performer of the European HbA1c Testing Market by occupying 22.3% of the share with its comprehensive diabetes care infrastructure, mandatory monitoring protocols, and advanced diagnostic ecosystem. Germany operates more than 1,200 accredited clinical laboratories, all participating in the DEKS external quality assurance program by ensuring high analytical standards. The Federal Joint Committee mandates that HbA1c results be integrated into electronic patient records for all disease management program participants, facilitating longitudinal tracking. This blend of regulatory enforcement, laboratory excellence, and digital integration creates a high-volume, high-quality testing environment that anchors the European market.

United Kingdom HbA1c Testing Market Analysis

The United Kingdom HbA1c Testing Market held 18.3% of share in 2024, with the centralized public health initiatives and performance-based primary care incentives. The National Health Service performs over 25 million HbA1c tests annually, with results feeding into the Quality and Outcomes Framework that rewards general practices for maintaining glycemic control in diabetic patients. The UK also hosts the National External Quality Assessment Service, which sets methodological standards adopted across the EU. Recent policy shifts encourage point-of-care testing, with the NHS Long Term Plan allocating funding for HbA1c analyzers in community hubs to reach underserved populations. Furthermore, the Medicines and Healthcare products Regulatory Agency actively evaluates home collection kits, with three receiving CE IVDR certification in 2024.

France HbA1c Testing Market Analysis

France HbA1c Testing Market growth is expected to have prominent growth opportunities in next coming years with its universal healthcare system and strong emphasis on preventive metabolic screening. The French National Health Insurance Fund reimburses two HbA1c tests per year for all diagnosed diabetics and covers diagnostic testing for high-risk individuals by resulting in over 18 million annual tests as per Santé Publique France. The country operates a nationwide network of 350 hospital-based biochemistry laboratories that adhere to the COFRAC accreditation standard by ensuring methodological consistency. France also pioneers integrated care models; the “Diabète Réseau” program connects primary care physicians with endocrinologists and dietitians, with HbA1c serving as the central monitoring metric.

Italy HbA1c Testing Market Analysis

Italy HbA1c Testing Market growth is propelled by a high diabetes prevalence and regional healthcare autonomy that fosters localized innovation. As per the Italian National Institute of Health, 4.1 million adults have been diagnosed with diabetes, with regional agencies in Lombardy and Emilia Romagna implementing aggressive screening programs that include HbAa 1first-linelinee diagnostic tool. The general practices in Northern Italy now use certified handheld devices, supported by regional funding. Additionally, Italy participates in the European External Quality Assessment Service and has adopted IFCC traceability across all public laboratories.

COMPETITIVE LANDSCAPE

The Europe HbA1c Testing Market is characterized by intense competition among global diagnostics leaders and specialized point of care manufacturers, all operating within a highly regulated and qquality-drivenenvironment. Competition centers on analytical accuracy, regulatory compliance with IVDR, and seamless integration into digital health infrastructures. Large players like Roche and Bio Rad dominate centralized laboratories through high throughput, standardized platforms, while Siemens and Afinion lead in point of care with certified handheld devices. The market is further shaped by national external quality assessment schemes that mandate method validation, creating high barriers to entry for new entrants. Differentiation increasingly hinges on data connectivity, remote service capabilities, and alignment with public health initiatives such as diabetes registries and preventive screening programs.

KEY MARKET PLAYERS

Some of the key players operating in the market are

• Transasia Biomedicals Ltd.
• Abbott Laboratories
• Alere, Inc.
• Arkray, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare
• Trinity Biotech plc.

TOP LEADING PLAYERS IN THE MARKET

• Bio Rad Laboratories is a global leader in clinical diagnostics with a strong presence in the European HbA1c Testing Market through its widely adopted Variant and D 100 HPLC platforms. The company’s systems are installed in thousands of hospitals and reference laboratories across the EU and are recognized for their precision, NGSP certification, and ability to detect hemoglobin variants. Bio Rad has reinforced its European position by enhancing connectivity features that integrate HbA1c results into laboratory information systems and national diabetes registries. Recently, the company launched software updates enabling remote diagnostics and predictive maintenance for its analyzers, reducing downtime in ihigh-volumeme labs. These innovations support compliance with the EU In Vitro Diagnostic Regulation while strengthening customer retention through service excellence and data interoperability.
• Roche Diagnostics plays a pivotal role in the European HbA1c Testing Market by offering enzymatic HbA1c assays fully integrated into its cobas clinical chemistry platforms. This seamless workflow allows laboratories to perform HbA1c testing alongside routine metabolic panels without dedicated instrumentation. Roche’s assays are IFCC traceable and CE IVDR certified, ensuring regulatory compliance across all EU member states. The company has recently expanded digital capabilities by linking HbA1c results to its NAVIFY digital health ecosystem, enabling longitudinal tracking and AI-driven insights for diabetes management. Roche also collaborates with national health agencies on pilot programs for preventive screening with its platform as a cornerstone of integrated metabolic care in both hospital and primary care settings throughout Europe.
• Siemens Healthineers maintains a significant footprint in the European HbA1c Testing Market through its portfolio of bench-top and point-of-care solutions, including the ADVIA Chemistry XPT and the Multicare In systems. The company emphasizes standardization and ease of use, with all HbA1c assays aligned to IFCC reference methods and certified by NGSP. Siemens has strengthened its position by enhancing interoperability between its laboratory and point-of-care devices by allowing unified data management across care settings. In recent years, the company has partnered with primary care networks in Germany and the Netherlands to deploy connected HbA1c analyzers that feed results directly into electronic health records. These initiatives support value-based care models and reinforce Siemens’ role as a provider of end-to-end diagnostic and digital health solutions for chronic disease management.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the Europe HbA1c Testing Market focus on achieving full compliance with IFCC and NGSP standardization to ensure result accuracy and cross platform comparability. They integrate HbA1c assays into broader clinical chemistry or point-of-care ecosystems to streamline workflows and reduce operational costs. Companies invest in digital connectivity to link test results with electronic health records and diabetes management platforms for longitudinal tracking. Strategic partnerships with national health systems and primary care networks accelerate adoption in preventive and community settings. Additionally, they enhance service offerings through remote diagnostics, predictive maintenance, and external quality assurance support to strengthen customer loyalty and regulatory adherence under the EU In Vitro Diagnostic Regulation.

MARKET SEGMENTATION

This research report on the europe HbA1c testing market has been segmented and sub-segmented into the following categories.

By Technology

• Ion-Exchange HPCL
• Enzymatic Assay
• Affinity Binding Chromatography
• Turbidimetric Inhibition Immunoassay
• Other

By Type

• Hand-Held Devices
• Bench Top Devices

By End User

• Hospital
• Home Care
• Diagnostic laboratory
• Research Institutions

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe